Tetsuya Yamagata

Company: Modalis Therapeutics

Job title: Chief Scientific Officer

Seminars:

Highlighting the Limited Immunogenicity Despite Sustained Cas-9 Expression 11:45 am

Explore how efficient and durable gene activation by Cas-9-mediated in vivo epigenome editing had limited immunogenicity Understand the impact of using an AAV delivery system on targeting Emphasize that despite sustained Cas-9 expression, good toxicology data shows therapeutic safetyRead more

day: Day Two